Intracranial hemorrhage with target specific oral anticoagulants in patients with atrial fibrillation: An updated meta-analysis of randomized controlled trials
Department of Medicine, Division of Cardiovascular Medicine
Cardiology | Cardiovascular Diseases
Although individual trials with Target Specific Oral Anticoagulants (TSOACs) have shown decreased rates of intracranial hemorrhage (ICH), there is limited data regarding the absolute and relative benefit of TSOACs in prevention of ICH. We performed a meta analysis to evaluate the absolute risk of ICH with TSOACs in patients with atrial fibrillation (AF), using data from the most recent clinical trials.
Rights and Permissions
Citation: Int J Cardiol. 2016 Jan 15;203:1000-2. doi: 10.1016/j.ijcard.2015.11.097. Epub 2015 Nov 17. Link to article on publisher's site
Apixaban, Atrial fibrillation, Dabigatran, Edoxaban, Intracranial hemorrhage, Rivaroxaban
Kundu, Amartya; Sen, Parijat; Sardar, Partha; Chatterjee, Saurav; Kapoor, Alok; and McManus, David D., "Intracranial hemorrhage with target specific oral anticoagulants in patients with atrial fibrillation: An updated meta-analysis of randomized controlled trials" (2016). University of Massachusetts Medical School Faculty Publications. 858.